CHRS - Coherus BioSciences, Inc.
18.62 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 19.18 |
| Open | 18.80 |
| Bid | 18.61 x 2200 |
| Ask | 21.95 x 900 |
| Day's Range | 17.50 - 19.14 |
| 52 Week Range | 8.32 - 23.91 |
| Volume | 2,171,954 |
| Avg. Volume | 1,073,644 |
| Market Cap | 1.299B |
| Beta (3Y Monthly) | 1.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.72 |
| Earnings Date | Nov 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.71 |
- Simply Wall St.
Are Insiders Selling Coherus BioSciences, Inc. (NASDAQ:CHRS) Stock?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Oct. 18, 2019 -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that effective October 17, 2019, the compensation.
- GlobeNewswire
Coherus BioSciences to Report Third Quarter Financial Results on November 6th
REDWOOD CITY, Calif., Oct. 15, 2019 -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its third quarter 2019 financial results will.
- Investor's Business Daily
How This IBD Stock Of The Day Is Rattling Medical Giants Amgen, Mylan
Coherus Biosciences is the IBD Stock Of The Day as shares of the biotech company flirt with a breakout on expectations for a strong third quarter. Coherus makes biosimilars of branded drugs.
- Zacks
Investors Can Find Big Returns with this First Profit Screen
Investors Can Find Big Returns with this First Profit Screen
- Zacks
Coherus BioSciences (CHRS) Upgraded to Buy: Here's What You Should Know
Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Thomson Reuters StreetEvents
Edited Transcript of CHRS earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Coherus BioSciences Inc Earnings Call
- Investor's Business Daily
Stocks To Watch: Is Biosimilars Leader Coherus Biosciences Set To Rebound?
Boosted by rebounding earnings and sales growth and a promising pipeline, biosimilars leader Coherus Biosciences is approaching a potential new buy.
- Simply Wall St.
Is Coherus BioSciences (NASDAQ:CHRS) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- GlobeNewswire
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in September
REDWOOD CITY, Calif., Aug. 21, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare.
Motley FoolCoherus BioSciences, Inc. (CHRS) Q2 2019 Earnings Call Transcript
CHRS earnings call for the period ending June 30, 2019.
- Zacks
Coherus BioSciences (CHRS) Beats Q2 Earnings and Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 500.00% and 2.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Coherus BioSciences Reports Corporate Highlights and Second Quarter 2019 Financial Results
– Company is Profitable and Cash flow Positive from Operations for Second Quarter – – UDENYCA® is the Market Leading Pegfilgrastim Biosimilar with Approximately 13% Market Share.
- GuruFocus.com
Steven Cohen Charges Into Chiasma
Guru invests in clinical-stage biopharmaceutical company Continue reading...
- GlobeNewswire
Coherus BioSciences Reports Victory in Pegfilgrastim Patent Dispute
REDWOOD CITY, Calif., July 29, 2019 -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that the United States Court of Appeals for the.
- Motley Fool
Why Deutsche Bank, Intra-Cellular Therapies, and Coherus BioSciences Slumped Today
Bad news on multiple fronts hit stocks.
- Motley Fool
Here's Why Coherus BioSciences Is Falling Today
The business reported an upbeat update, but something got lost in translation on Wall Street.
- Simply Wall St.
Are Investors Undervaluing Coherus BioSciences, Inc. (NASDAQ:CHRS) By 20%?
Today we will run through one way of estimating the intrinsic value of Coherus BioSciences, Inc. (NASDAQ:CHRS) by...
- GlobeNewswire
Coherus BioSciences Announces Unaudited Second Quarter 2019 UDENYCA® Net Sales of $79 Million to $84 Million
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Coherus’ expectations regarding the continued adoption of UDENYCA® in the U.S., estimation of channel mix, returns, chargebacks and rebates, each of which impact net sales computation. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made.
- GlobeNewswire
Coherus BioSciences to Report Second Quarter Financial Results on August 1st
REDWOOD CITY, Calif., July 08, 2019 -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its second quarter 2019 financial results will.
- GlobeNewswire
Coherus BioSciences Production Exceeds Four-Hundred Thousand UDENYCA® (pegfilgrastim-cbqv) Pre-Filled Syringes
Coherus BioSciences, Inc. (“Coherus” or “the Company,” Nasdaq: CHRS), is pleased to announce that it has produced over 400,000 UDENYCA® pre-filled syringes to date. The cumulative production of 400,000 UDENYCA® pre-filled syringes is a significant milestone, as it represents approximately one-third of the annual utilization of pegfilgrastim in the United States. “Coherus provides unencumbered choice of pegfilgrastim product to patients and providers in the United States," said Denny Lanfear, President and CEO of Coherus.
